How do regulatory changes address the affordability and accessibility of cancer treatments?
Regulatory changes aim to address the affordability and accessibility of cancer treatments by promoting the use of biosimilars and generic drugs. These alternatives offer similar efficacy at a lower cost, making treatments more accessible to a broader patient population. Additionally, regulatory agencies are working on frameworks to ensure that innovative therapies, such as CAR-T cells and gene therapies, are priced reasonably and distributed equitably.
